Quick Takeaways
- Affinity Asset Advisors, LLC filed SCHEDULE 13G/A for Avalo Therapeutics, Inc. Common Stock, $0.001 par value per share (AVTX).
- Disclosed ownership: 5.7%.
- Date of event: 22 Jan 2026.
Affinity Asset Advisors, LLC - 22 Jan 2026 SCHEDULE 13G/A Report for Avalo Therapeutics, Inc. Common Stock, $0.001 par value per share (AVTX)
- Filing Manager
- Affinity Asset Advisors, LLC
- Reporting Manager
- Affinity Asset Advisors, LLC
- Symbol
- AVTX
- Shares outstanding
- 18,439,544 shares
- Disclosed Ownership
- 1,051,054 shares
- Ownership
- 5.7%
- Form type
- SCHEDULE 13G/A
- Filing time
- 29 Jan 2026, 19:56:26 UTC
- Date of event
- 22 Jan 2026
- Previous filing
- 13 Nov 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Affinity Asset Advisors, LLC disclosed 5.7% ownership in Avalo Therapeutics, Inc. Common Stock, $0.001 par value per share (AVTX) on 22 Jan 2026."
What Changed
- Previous schedule filing date: 13 Nov 2025.
- Current filing was accepted on 29 Jan 2026, 19:56.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Affinity Asset Advisors, LLC | 5.7% | 1,051,054 | 1,051,054 | 0 | /s/ Andrew Weinstein | Andrew Weinstein, Chief Financial Officer and Chief Compliance Officer | |
| Michael Cho | 5.7% | 1,051,054 | 1,051,054 | 0 | /s/ Michael Cho | Michael Cho, Self |